Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

Treatment of African green monkeys with remdesivir (GS-5734) 24 hours after lethal Nipah virus challenge resulted in 100% survival. Nipping Nipah virus infections in the bud Human infection with Nipah virus is often fatal, and there are no approved therapeutics. Lo et al. tested the nucleotide prodrug remdesivir (GS-5734), which has shown activity against other pathogens such as Ebola virus, in a nonhuman primate model. Animals were administered a lethal dose of Nipah virus, and half were treated daily with remdesivir starting 24 hours later. All control animals had to be euthanized, and although treated animals had some mild symptoms, all survived. These results indicate that efficacy of remdesivir should be tested in human Nipah virus infection. Nipah virus is an emerging pathogen in the Paramyxoviridae family. Upon transmission of Nipah virus from its natural reservoir, Pteropus spp. fruit bats, to humans, it causes respiratory and neurological disease with a case-fatality rate about 70%. Human-to-human transmission has been observed during Nipah virus outbreaks in Bangladesh and India. A therapeutic treatment for Nipah virus disease is urgently needed. Here, we tested the efficacy of remdesivir (GS-5734), a broad-acting antiviral nucleotide prodrug, against Nipah virus Bangladesh genotype in African green monkeys. Animals were inoculated with a lethal dose of Nipah virus, and a once-daily intravenous remdesivir treatment was initiated 24 hours later and continued for 12 days. Mild respiratory signs were observed in two of four treated animals, whereas all control animals developed severe respiratory disease signs. In contrast to control animals, which all succumbed to the infection, all remsdesivir-treated animals survived the lethal challenge, indicating that remdesivir represents a promising antiviral treatment for Nipah virus infection.

[1]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[2]  R. Prassl,et al.  Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements , 2020, Life Sciences.

[3]  M. Porotto,et al.  Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates , 2018, The Journal of infectious diseases.

[4]  V. R. Rajendran,et al.  Outbreak Investigation of Nipah Virus Disease in Kerala, India, 2018. , 2018, The Journal of infectious diseases.

[5]  J. Guarner,et al.  Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. , 2002, The American journal of pathology.

[6]  Ashish Ranjan Sharma,et al.  Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More , 2020, Archives of Medical Research.

[7]  P. Daszak,et al.  Evolving epidemiology of Nipah virus infection in Bangladesh: evidence from outbreaks during 2010–2011 , 2015, Epidemiology and Infection.

[8]  T. Ksiazek,et al.  Laboratory diagnosis of Nipah and Hendra virus infections. , 2001, Microbes and infection.

[9]  K. Rahmat,et al.  Late-onset Nipah virus encephalitis 11 years after the initial outbreak: A case report , 2012 .

[10]  A. Hasan,et al.  Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase , 2020, Journal of biomolecular structure & dynamics.

[11]  Benhur Lee,et al.  Favipiravir (T-705) protects against Nipah virus infection in the hamster model , 2018, Scientific Reports.

[12]  C. Broder,et al.  Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy , 2016, Scientific Reports.

[13]  M. Wong,et al.  Late presentation of Nipah virus encephalitis and kinetics of the humoral immune response , 2001, Journal of neurology, neurosurgery, and psychiatry.

[14]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[15]  J. Sejvar,et al.  Long‐term neurological and functional outcome in Nipah virus infection , 2007, Annals of neurology.

[16]  H. Feldmann,et al.  Effective Chemical Inactivation of Ebola Virus , 2016, Emerging infectious diseases.

[17]  Tchoyoson C. C. Lim,et al.  Nipah Virus Infection , 2018, Journal of Clinical Microbiology.

[18]  A. Arvey,et al.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses , 2017, Scientific Reports.

[19]  A. Sugunan,et al.  Infections among Contacts of Patients with Nipah Virus, India , 2019, Emerging infectious diseases.

[20]  K. Tan,et al.  Relapsed and late‐onset Nipah encephalitis , 2002, Annals of neurology.

[21]  G. Wilkie,et al.  Late Ebola virus relapse causing meningoencephalitis: a case report , 2016, The Lancet.

[22]  E. Abu-Gharbieh,et al.  The Rationale for Potential Pharmacotherapy of COVID-19 , 2020, Pharmaceuticals.

[23]  Joe Pardo,et al.  The journey of remdesivir: from Ebola to COVID-19 , 2020, Drugs in context.

[24]  V. R. Rajendran,et al.  Nipah Virus Sequences from Humans and Bats during Nipah Outbreak, Kerala, India, 2018 , 2019, Emerging infectious diseases.

[25]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[26]  A. McElroy,et al.  First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease , 2017, The Journal of infectious diseases.

[27]  C. Broder,et al.  Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody , 2014, Science Translational Medicine.